DK4067496T3 - ADAM6-mus - Google Patents

ADAM6-mus Download PDF

Info

Publication number
DK4067496T3
DK4067496T3 DK22156414.9T DK22156414T DK4067496T3 DK 4067496 T3 DK4067496 T3 DK 4067496T3 DK 22156414 T DK22156414 T DK 22156414T DK 4067496 T3 DK4067496 T3 DK 4067496T3
Authority
DK
Denmark
Prior art keywords
adam6 mice
adam6
mice
Prior art date
Application number
DK22156414.9T
Other languages
English (en)
Other versions
DK4067496T5 (da
Inventor
Andrew J Murphy
Lynn Macdonald
Sean Stevens
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4067496(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of DK4067496T3 publication Critical patent/DK4067496T3/da
Application granted granted Critical
Publication of DK4067496T5 publication Critical patent/DK4067496T5/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK22156414.9T 2011-02-25 2012-02-24 ADAM6-mus DK4067496T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
EP20170540.7A EP3744850A1 (en) 2011-02-25 2012-02-24 Adam6 mice

Publications (2)

Publication Number Publication Date
DK4067496T3 true DK4067496T3 (da) 2023-06-26
DK4067496T5 DK4067496T5 (da) 2024-07-22

Family

ID=45998616

Family Applications (6)

Application Number Title Priority Date Filing Date
DK14154967.5T DK2738259T3 (da) 2011-02-25 2012-02-24 ADAM6-mus
DK14176593.3T DK2813573T1 (da) 2011-02-25 2012-02-24 ADAM6 mus
DK22156414.9T DK4067496T5 (da) 2011-02-25 2012-02-24 ADAM6-mus
DK12716101.6T DK2550363T3 (da) 2011-02-25 2012-02-24 ADAM6-mus
DK12192727.1T DK2578688T4 (da) 2011-02-25 2012-02-24 ADAM6-mus
DK14154918.8T DK2738258T4 (da) 2011-02-25 2012-02-24 ADAM6-mus

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK14154967.5T DK2738259T3 (da) 2011-02-25 2012-02-24 ADAM6-mus
DK14176593.3T DK2813573T1 (da) 2011-02-25 2012-02-24 ADAM6 mus

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK12716101.6T DK2550363T3 (da) 2011-02-25 2012-02-24 ADAM6-mus
DK12192727.1T DK2578688T4 (da) 2011-02-25 2012-02-24 ADAM6-mus
DK14154918.8T DK2738258T4 (da) 2011-02-25 2012-02-24 ADAM6-mus

Country Status (32)

Country Link
US (11) US8642835B2 (da)
EP (7) EP3744850A1 (da)
JP (7) JP2014507137A (da)
KR (1) KR101387377B1 (da)
CN (2) CN103429746B (da)
AU (5) AU2012243291B2 (da)
BR (1) BR112013021771B1 (da)
CA (1) CA2820824A1 (da)
CY (5) CY1116301T1 (da)
DE (5) DE12716101T1 (da)
DK (6) DK2738259T3 (da)
ES (6) ES2758974T5 (da)
FI (3) FI2578688T4 (da)
HK (2) HK1174490A1 (da)
HR (5) HRP20192311T4 (da)
HU (5) HUE047687T2 (da)
IL (4) IL226727A (da)
IN (1) IN2013CN07629A (da)
LT (4) LT2578688T (da)
ME (3) ME03537B (da)
MX (2) MX343009B (da)
MY (1) MY172713A (da)
NZ (2) NZ731926A (da)
PL (5) PL4067496T3 (da)
PT (5) PT4067496T (da)
RS (5) RS59661B2 (da)
RU (2) RU2722373C2 (da)
SG (4) SG10201405135RA (da)
SI (5) SI2550363T1 (da)
SM (1) SMT201500061B (da)
WO (1) WO2012141798A1 (da)
ZA (1) ZA201305998B (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ATE514717T1 (de) 2002-07-18 2011-07-15 Merus B V Rekombinante produktion von antikörpermischungen
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
KR101443473B1 (ko) 2004-07-22 2014-09-22 에라스무스 유니버시티 메디컬 센터 로테르담 Ｖh 결합 영역의 분리 방법
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2792236B2 (en) 2009-07-08 2023-03-22 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
HUE045591T2 (hu) 2010-02-08 2019-12-30 Regeneron Pharma Közönséges könnyûláncú egér
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
RU2750219C2 (ru) 2010-08-02 2021-06-24 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
RS59661B2 (sr) 2011-02-25 2023-06-30 Regeneron Pharma Adam6 miševi
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
MY172718A (en) * 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
AU2012311288B2 (en) 2011-09-19 2017-08-17 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
HUE057680T2 (hu) * 2011-10-17 2022-06-28 Regeneron Pharma Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
CA2859408C (en) * 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
RS59699B1 (sr) * 2012-02-01 2020-01-31 Regeneron Pharma Humanizovani miševi koji eksprimiraju teške lance koji sadrže vl domene
MY172730A (en) 2012-03-16 2019-12-11 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
MX2014011047A (es) 2012-03-16 2015-04-08 Regeneron Pharma Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph.
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
KR102459666B1 (ko) 2012-03-16 2022-10-27 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
PL3597037T3 (pl) * 2012-06-12 2021-10-25 Regeneron Pharmaceuticals, Inc. Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny
SG11201505713YA (en) 2013-02-06 2015-08-28 Regeneron Pharma B cell lineage based immunogen design with humanized animals
MY178882A (en) * 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
PL2967012T3 (pl) * 2013-03-14 2021-04-19 Erasmus University Medical Center Rotterdam Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
WO2015143414A2 (en) * 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CA2959428A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
CN108777951B (zh) 2016-01-13 2021-11-05 瑞泽恩制药公司 具有包括改造的多样性簇的免疫球蛋白重链可变区的非人动物及其用途
RU2018130010A (ru) 2016-02-16 2020-03-17 Регенерон Фармасьютикалз, Инк. Животные, отличные от человека, имеющие мутантный ген кинурениназы
KR102628909B1 (ko) * 2016-05-20 2024-01-25 리제너론 파마슈티칼스 인코포레이티드 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
PT3462853T (pt) 2016-06-03 2023-04-21 Regeneron Pharma Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
AU2017391167B2 (en) 2016-11-04 2024-02-15 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
WO2018226861A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US20210345591A1 (en) 2017-12-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
CN112040769B (zh) 2018-03-24 2023-05-16 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途
SG11202008620VA (en) 2018-03-26 2020-10-29 Regeneron Pharma Humanized rodents for testing therapeutic agents
US20210079109A1 (en) 2018-05-17 2021-03-18 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
CN112312766A (zh) 2018-06-14 2021-02-02 瑞泽恩制药公司 在免疫球蛋白重链编码序列中具有dh-dh重排能力的非人动物
CN117099741A (zh) 2019-02-18 2023-11-24 百奥赛图(北京)医药科技股份有限公司 具有人源化免疫球蛋白基因座的经遗传修饰的非人动物
CA3127153A1 (en) 2019-02-22 2020-08-27 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
US20220330532A1 (en) 2019-06-05 2022-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
DK3785536T3 (da) * 2019-08-28 2022-03-28 Trianni Inc Adam6-knockin-mus
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
CA3182925A1 (en) 2020-06-02 2021-12-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
JP2023540808A (ja) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗原特異的抗体の同定及び産生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
TW202241934A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 編碼錨定修飾抗體之核酸及其用途
BR112023011689A2 (pt) 2020-12-23 2023-10-31 Regeneron Pharma Método para obter uma célula produtora de anticorpos, anticorpo, e, célula hospedeira de mamífero
KR20230171454A (ko) 2021-04-20 2023-12-20 리제너론 파마슈티칼스 인코포레이티드 아르테민에 대한 인간 항체 및 이의 사용 방법
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0671951A4 (en) * 1992-12-01 1997-05-21 Protein Design Labs Inc HUMANIZED ANTIBODIES REACTING WITH L-SELECTIN.
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
AU5043200A (en) * 1999-05-27 2000-12-18 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
JP4115281B2 (ja) * 2001-05-11 2008-07-09 キリンファーマ株式会社 ヒト抗体λ軽鎖遺伝子を含むヒト人工染色体、および子孫伝達可能な該ヒト人工染色体を含む非ヒト動物
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
ATE514717T1 (de) 2002-07-18 2011-07-15 Merus B V Rekombinante produktion von antikörpermischungen
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
EP1739691B1 (en) 2005-06-30 2008-12-03 Borealis Technology Oy Outer sheath layer for power or communication cable
JP5514539B2 (ja) 2006-03-31 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
WO2009097006A2 (en) 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
ES2613730T3 (es) * 2008-12-18 2017-05-25 Erasmus University Medical Center Rotterdam Animales transgénicos no humanos que expresan anticuerpos humanizados y su uso
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
EP2792236B2 (en) 2009-07-08 2023-03-22 Kymab Limited Animal models and therapeutic molecules
SG181477A1 (en) 2009-12-10 2012-07-30 Regeneron Pharma Mice that make heavy chain antibodies
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
HUE045591T2 (hu) 2010-02-08 2019-12-30 Regeneron Pharma Közönséges könnyûláncú egér
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
RS59661B2 (sr) 2011-02-25 2023-06-30 Regeneron Pharma Adam6 miševi
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
HUE057680T2 (hu) 2011-10-17 2022-06-28 Regeneron Pharma Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CA2859408C (en) 2011-12-20 2020-06-16 Regeneron Pharmaceuticals, Inc. Humanized light chain mice

Also Published As

Publication number Publication date
US20180346599A1 (en) 2018-12-06
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
CN103429746B (zh) 2016-05-11
HUE046746T2 (hu) 2020-03-30
DK2578688T1 (da) 2014-11-24
EP2550363A1 (en) 2013-01-30
PT2738258T (pt) 2019-12-10
IN2013CN07629A (da) 2015-08-07
SI2738258T2 (sl) 2023-05-31
US20180362663A1 (en) 2018-12-20
EP2738258B2 (en) 2023-02-01
HUE062552T2 (hu) 2023-11-28
JP2022071051A (ja) 2022-05-13
US20150210776A1 (en) 2015-07-30
SI2578688T1 (sl) 2019-11-29
DK2738258T4 (da) 2023-05-08
CN103429746A (zh) 2013-12-04
RU2016109443A3 (da) 2019-07-24
ME03732B (me) 2021-01-20
ES2748832T5 (es) 2023-06-08
PL2738259T3 (pl) 2020-08-24
EP4067496A1 (en) 2022-10-05
JP2018143250A (ja) 2018-09-20
LT2578688T (lt) 2019-11-11
RS59413B1 (sr) 2019-11-29
ME02106B (me) 2015-10-20
WO2012141798A1 (en) 2012-10-18
RS64280B1 (sr) 2023-07-31
PL2578688T5 (pl) 2023-05-29
DE14154967T1 (de) 2014-08-28
US9944716B2 (en) 2018-04-17
IL268671B (en) 2020-05-31
JP5866127B2 (ja) 2016-02-17
EP2578688B2 (en) 2023-02-08
EP2738258A2 (en) 2014-06-04
EP2738258A3 (en) 2014-09-24
EP2738259B1 (en) 2019-11-27
NZ718688A (en) 2017-07-28
MY172713A (en) 2019-12-11
SG10201913160QA (en) 2020-03-30
US9932408B2 (en) 2018-04-03
HRP20200294T1 (hr) 2020-05-29
ES2946169T3 (es) 2023-07-13
EP2578688A1 (en) 2013-04-10
US20130254911A1 (en) 2013-09-26
IL261243B (en) 2019-08-29
DE14176593T1 (de) 2015-03-05
FI2738258T4 (fi) 2023-05-05
RS59661B2 (sr) 2023-06-30
HRP20230526T1 (hr) 2023-09-01
ZA201305998B (en) 2016-07-27
US20210105985A1 (en) 2021-04-15
SG10201405135RA (en) 2014-10-30
JP2019187446A (ja) 2019-10-31
US20120322108A1 (en) 2012-12-20
HRP20191895T4 (hr) 2023-05-12
DK2738258T3 (da) 2019-12-16
IL273986A (en) 2020-05-31
MX2013009649A (es) 2013-09-26
HUE024534T2 (hu) 2016-01-28
DE12192727T1 (de) 2013-07-11
PL4067496T3 (pl) 2023-07-31
SG10201913155QA (en) 2020-02-27
EP2738259A2 (en) 2014-06-04
SMT201500061B (it) 2015-05-05
HK1174490A1 (en) 2013-06-14
DE12716101T1 (de) 2013-05-08
US20180345760A1 (en) 2018-12-06
AU2020201279A1 (en) 2020-03-12
DK2578688T3 (da) 2019-10-28
BR112013021771B1 (pt) 2022-11-16
EP2813573A1 (en) 2014-12-17
RU2582261C2 (ru) 2016-04-20
EP2550363B1 (en) 2014-12-10
NZ703609A (en) 2016-04-29
NZ731926A (en) 2021-07-30
RU2016109443A (ru) 2018-11-26
HRP20192311T4 (hr) 2023-05-12
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
MX343009B (es) 2016-10-21
CY1122459T1 (el) 2021-01-27
DK2738259T3 (da) 2020-02-17
RS53880B1 (en) 2015-08-31
IL268671A (en) 2019-10-31
JP2016135143A (ja) 2016-07-28
CY1116301T1 (el) 2017-02-08
DK2738259T1 (da) 2014-11-24
DK2813573T1 (da) 2015-01-12
PT2738259T (pt) 2020-02-18
ES2758974T5 (es) 2023-06-08
RS59413B2 (sr) 2023-06-30
ES2532487T3 (es) 2015-03-27
FI4067496T3 (fi) 2023-05-24
CY1126091T1 (el) 2023-11-15
US20150201589A1 (en) 2015-07-23
IL273986B (en) 2021-04-29
PL2550363T3 (pl) 2015-05-29
AU2022206806A1 (en) 2022-08-18
US20180346598A1 (en) 2018-12-06
SI2738259T1 (sl) 2020-06-30
US8642835B2 (en) 2014-02-04
SI2578688T2 (sl) 2023-05-31
KR101387377B1 (ko) 2014-04-21
AU2012243291A1 (en) 2013-05-09
BR112013021771A2 (pt) 2017-07-04
EP2738259A3 (en) 2014-07-30
NZ776770A (en) 2023-03-31
SI2738258T1 (sl) 2020-01-31
DE14154918T1 (de) 2014-08-21
EP2813573B1 (en) 2020-04-22
HUE047687T2 (hu) 2020-05-28
SG192933A1 (en) 2013-09-30
US10694725B2 (en) 2020-06-30
PT4067496T (pt) 2023-06-07
HRP20192311T1 (hr) 2020-03-20
PL2738258T3 (pl) 2020-08-24
AU2012243291B2 (en) 2015-07-09
ES2748832T3 (es) 2020-03-18
RU2013125717A (ru) 2014-12-10
US10905109B2 (en) 2021-02-02
EP4067496B1 (en) 2023-03-29
AU2015238806A1 (en) 2015-10-29
DK2578688T4 (da) 2023-05-08
AU2017251802A1 (en) 2017-11-16
PL2578688T3 (pl) 2020-05-18
FI2578688T4 (fi) 2023-05-05
CA2820824A1 (en) 2012-10-18
US10577430B2 (en) 2020-03-03
RU2722373C2 (ru) 2020-05-29
IL261243A (en) 2018-10-31
IL226727A (en) 2016-08-31
JP2014110814A (ja) 2014-06-19
PT2550363E (pt) 2015-03-16
CY1122820T1 (el) 2021-05-05
KR20130116375A (ko) 2013-10-23
DK2738258T1 (da) 2014-11-24
US8697940B2 (en) 2014-04-15
EP3744850A1 (en) 2020-12-02
ES2770424T3 (es) 2020-07-01
EP2738258B1 (en) 2019-09-25
JP2014507137A (ja) 2014-03-27
HK1201292A1 (en) 2015-08-28
JP2015107131A (ja) 2015-06-11
US20210105984A1 (en) 2021-04-15
US10905108B2 (en) 2021-02-02
CN105861548A (zh) 2016-08-17
CN105861548B (zh) 2020-01-10
EP2578688B1 (en) 2019-07-24
LT2738258T (lt) 2020-01-10
RS59929B1 (sr) 2020-03-31
ES2805364T3 (es) 2021-02-11
CY1122205T1 (el) 2020-11-25
HRP20191895T1 (hr) 2020-01-10
HRP20150262T1 (hr) 2015-04-10
US10072095B2 (en) 2018-09-11
NZ612643A (en) 2015-06-26
DK2550363T3 (da) 2015-03-23
MX2020009714A (es) 2020-10-07
RS59661B1 (sr) 2020-01-31
LT4067496T (lt) 2023-06-12
SI4067496T1 (sl) 2023-07-31
DK4067496T5 (da) 2024-07-22
LT2738259T (lt) 2020-03-10
ME03537B (da) 2020-04-20
US20140213773A1 (en) 2014-07-31
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
DK2738258T3 (da) ADAM6-mus
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
BR112014002399A2 (pt) conjunto
DK2769050T3 (da) Propsensor
BR112014000879A2 (pt) deflegmador
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
DE102011100082A8 (de) Traygreifvorrichtung
DK3141251T3 (da) Koloskopi - forberedelse
DE112011104936A5 (de) Stanzstauchniet
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild
DK2526750T3 (da) Høbjærgningsmaskine
DE112012001294T8 (de) Umspritzungsverfahren
DE102011117169A8 (de) Absetzplattenanordnung
DE112011105396A5 (de) Nachverfestigungsverfahren
DK2681057T3 (da) Nanofiber-mærkning
ES1076319Y (es) Minisalvavidas acuatico
ES1075696Y (es) Calzoncillo
ES1075978Y (es) Cucharon-colador-trasvasador
ES1075621Y (es) Minialetas
FI20110275A0 (fi) Kelaualaite